What Steba Biotech does

Steba Biotech, operating under the name ImPact Biotech, is a privately held, clinical-stage biotechnology company founded in 1996 and headquartered in New York, United States. The firm is built around a single proprietary platform — Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) — a light-activated oncology technology designed to deliver surgery-like efficacy for the treatment of solid tumors in patients who are ineligible for surgical intervention or for whom surgery would be debilitating. The platform's core mechanism uses a photosensitizer activated by targeted illumination to disrupt tumor vasculature, enabling precise, organ-sparing treatment across multiple solid tumor indications.

The company is applying Padeliporfin VTP across a development pipeline covering four oncology indications: Upper Tract Urothelial Carcinoma (UTUC), Lung Cancer, Esophageal Cancer, and Pancreatic Cancer. All four programs are pipeline-stage with no commercialized product. The organization's stated go-to-market posture is to actively seek strategic and co-development partnerships to advance the platform, rather than build a standalone commercial sales force; investor relations and partnership outreach appear to be the primary commercial channels currently active.

Steba Biotech operates with 1-10 employees and discloses no commercial revenue, pricing, or customer base. The leadership team identified in available sources includes Barak Palatchi as CEO and Raphael Harari as Founder. The business model is therefore pre-commercial: value is generated through clinical advancement of the VTP platform, capture of development-stage milestones, and eventual partnership or licensing revenue tied to regulatory progress. Distribution channels, pricing models, and named institutional investors are not disclosed in the input data.

Name

Steba Biotech

Legal name

ImPact Biotech

Website

https://stebabiotech.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

Steba Biotech (operating as ImPact Biotech) is a clinical-stage biotechnology company developing Padeliporfin VTP, a vascular-targeted photodynamic therapy platform that treats solid tumors in patients ineligible for or unsuitable for surgery.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

akta.pro secondary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Vascular targeted photodynamic therapy
• Solid tumor oncology
• Photo-activated cancer therapy
• Biopharmaceutical drug development
• Oncology therapeutics pipeline

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Steba Biotech (operating as ImPact Biotech) is a private biopharmaceutical company developing Padeliporfin VTP (Vascular Targeted Photodynamic therapy), a targeted oncology platform for the treatment of solid tumors. The platform uses the drug Padeliporfin activated by targeted laser light to selectively destroy tumor vasculature, with a development pipeline targeting UTUC, lung, esophageal, and pancreatic cancers.

Product overview

ImPact Biotech (Steba Biotech) operates a single-platform approach built around its core Padeliporfin VTP (Vascular Targeted Photodynamic) technology. This novel oncology platform is designed to treat solid tumors by using light-activated therapy that targets tumor vasculature. The platform is being applied across multiple cancer indications in the development pipeline, including Upper Tract Urothelial Carcinoma (UTUC), Lung Cancer, Esophageal Cancer, and Pancreatic Cancer. The VTP technology offers surgery-like efficacy as an alternative for patients who are ineligible for surgery or for whom surgery would be debilitating.

Differentiator

Problem solved

Functional benefit

Products and services

• Padeliporfin VTP (Vascular Targeted Photodynamic Therapy) Padeliporfin VTP is a proprietary photo-activated oncology platform that uses the drug Padeliporfin combined with targeted laser light to selectively destroy tumor vasculature. It is being developed as a treatment for solid tumors and is intended for oncology specialists and hospital oncology/urology departments.
• Padeliporfin VTP for Upper Tract Urothelial Carcinoma (UTUC) An application of Steba Biotech's Padeliporfin VTP platform targeting Upper Tract Urothelial Carcinoma (UTUC), a rare urological cancer of the upper urinary tract. In development stage, intended for urology and oncology specialists treating UTUC patients.
• Padeliporfin VTP for Lung Cancer An application of Steba Biotech's Padeliporfin VTP platform targeting lung cancer. In development stage, intended for thoracic oncologists and pulmonology/oncology departments.
• Padeliporfin VTP for Esophageal Cancer An application of Steba Biotech's Padeliporfin VTP platform targeting esophageal cancer. In development stage, intended for gastroenterology oncologists and oncology departments.
• Padeliporfin VTP for Pancreatic Cancer An application of Steba Biotech's Padeliporfin VTP platform targeting pancreatic cancer. In development stage, intended for gastrointestinal oncologists and oncology surgical departments.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Open to PartneringcoreStrategic or Co-development PartnerImPact Biotech is actively seeking partnerships with organizations that share their vision for transforming the treatment paradigm in oncology. The company emphasizes that transforming treatment paradigms requires both innovation and strong collaborations. They welcome inquiries from organizations interested in working with ImPact Biotech to advance their VTP technology platform.

Recent moves3 records

Expansion highlights4 records

Direct peers

• Rakuten Medical: Rakuten Medical develops photoimmunotherapy (Alluminox platform), a light-activated oncology therapy that selectively targets tumor cells. It is the most directly comparable peer to ImPact Biotech, as both pursue light-activated, vascular- or cell-targeted oncology platforms in solid tumors.
• Theralase Technologies: Theralase is a clinical-stage photodynamic therapy company developing light-activated drug conjugates for non-muscle invasive bladder cancer and other solid tumors. It competes with ImPact Biotech in the PDT-oncology space, particularly for urological indications like UTUC.
• PhotoCure: PhotoCure commercializes Hexvix/Cysview, a photodynamic diagnostic and therapy platform used in bladder cancer management. It is a directly relevant peer in the PDT space and shares the urology-oncology overlap relevant to ImPact Biotech's UTUC program.
• Biolitec Pharma: Biolitec develops and commercializes laser-based photodynamic therapy systems and photosensitizing drugs for multiple solid tumor and benign indications. It is a direct commercial peer in the broader oncology PDT market.
• UroGen Pharma: UroGen Pharma develops specialty therapeutics for urothelial cancers, including Jelmyto for upper tract urothelial carcinoma (UTUC) — the same lead indication targeted by ImPact Biotech. It is a directly relevant peer for the UTUC opportunity.

Emerging players

• Soligenix: Soligenix is developing SGX301 (synthetic hypericin) photodynamic therapy for cutaneous T-cell lymphoma and has oncology and PDT expertise. It is an emerging peer with narrower indications but a directly comparable light-activated oncology mechanism.

Others

• Modulight: Modulight manufactures medical laser systems used as the light-delivery component in photodynamic therapy, including oncology applications. It is a key enabling technology supplier to PDT developers like ImPact Biotech rather than a direct competitor.

Broad incumbents

• AstraZeneca: AstraZeneca is a broad incumbent in oncology with approved therapies across lung, esophageal, and other solid tumors that overlap with ImPact Biotech's pipeline indications. It is relevant as a competitive force and a potential strategic acquirer or partner.
• Bristol-Myers Squibb: Bristol-Myers Squibb is a major oncology incumbent with leading immunotherapy franchises (Opdivo, Yervoy) targeting lung and other solid tumors overlapping with ImPact Biotech's pipeline. It represents the competitive standard of care in multiple ImPact indications.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals markets Zepzelca (lurbinectedin) for small cell lung cancer and has a broader oncology specialty franchise, including in urological cancers. It is a relevant commercial peer in ImPact Biotech's lung and UTUC indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/steba-biotech-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Steba Biotech